問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Infectious Disease

Division of Pediatrics

China Medical University Hospital-Taipei (在職)

Division of Infectious Disease

更新時間：2023-09-19

黃高彬Hwang, Kao-Pin
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

  • kapihw@mail.cmuh.org.tw

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃高彬

List

22Cases

2020-12-15 - 2022-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-08-30 - 2022-08-30

Phase II/III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2022-10-11 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-12-01 - 2025-08-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2018-06-01 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated7Sites

2021-08-01 - 2024-08-01

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-01-01 - 2023-01-24

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Terminated7Sites

2021-01-30 - 2022-03-31

Phase II

A phase II,Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of UB-612 Vaccine against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers

  • Condition/Disease

    COVID-19

  • Test Drug

    UB-612

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2021-07-15 - 2021-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-09-01 - 2021-05-31

Phase I

A phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of UB-612 vaccine in healthy adult volunteers

  • Condition/Disease

    Prevent COVID-19 infection

  • Test Drug

    UB-612

Participate Sites
1Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Infectious Disease

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB